BHV-7000 Acute Treatment of Bipolar Mania
NCT06419582Phase 2/3Completed
- Lead sponsor
- Biohaven Therapeutics Ltd. (Industry)
- Enrollment
- 274 (actual)
- Start date
- 28 May 2024
- Primary completion
- 15 Jan 2025 (actual)
- Study completion
- 30 Jan 2025
- Last update posted
- 16 Dec 2025
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- BHV-7000 Drug
- Placebo Drug
Conditions and primary outcome
- Bipolar Disorder
Primary outcome
Change in Young Mania Rating Scale (YMRS) total score from baseline to day 21 (Baseline (day 1) to day 21)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06419582.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06419582 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.